202 results
Page 3 of 11
6-K
EX-99.1
iwf 9gc81d52
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
jpgugx3kzf 6p
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
rhdfjsx5hzth
30 May 23
Current report (foreign)
6:11am
6-K
6okwcd953udgfzx44
17 May 23
Current report (foreign)
6:02am
6-K
i4uh90bo8m1ay3e3ibq
11 May 23
Current report (foreign)
6:10am
6-K
hb6mhy
11 May 23
Current report (foreign)
6:07am
6-K
qtwq0fviz 5k
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
vyk93
21 Dec 22
Current report (foreign)
6:01am
6-K
vkigep3ub0314rmu
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
2bl6s6
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
z64ioi1x8cm9s025qwbi
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
jh1o96ejzb0pv15
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
dm8ylgk
30 Nov 22
Current report (foreign)
6:28am
6-K
q8fob u7ewco7l9
4 Nov 22
Current report (foreign)
6:01am
6-K
z60wnyof3
27 Oct 22
Current report (foreign)
6:01am
6-K
yy7rktyc
14 Oct 22
Current report (foreign)
7:36am
6-K
s5jvyr64bn6k65uyyyh
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
czl6lmwz90hsneb hi
23 Aug 22
Current report (foreign)
6:13am
6-K
2xclfm385s8x1xx
4 Aug 22
Current report (foreign)
6:07am
6-K
ocqi9dvk0t
28 Jul 22
Current report (foreign)
6:09am